Comparison of Lipophilic Versus Hydrophilic Statins on Patients With Heart Failure
NCT ID: NCT03255044
Last Updated: 2020-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
85 participants
INTERVENTIONAL
2017-06-15
2019-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atorvastatin/CoenzymeQ10 in Congestive Heart Failure
NCT01925937
Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study
NCT03186404
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
NCT05511766
Pharmacological Regulation of Fat Transport in Metabolic Syndrome
NCT00632840
Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
NCT00452842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lipophilic statin
Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
Atorvastatin
Atorvastatin administered as well as standard heart failure therapy
guideline directed therapy
standard heart failure therapy
Hydrophilic statin
Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.
Rosuvastatin
Rosuvastatin administered as well as standard heart failure therapy
guideline directed therapy
standard heart failure therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Atorvastatin administered as well as standard heart failure therapy
Rosuvastatin
Rosuvastatin administered as well as standard heart failure therapy
guideline directed therapy
standard heart failure therapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with stable chronic heart failure NYHA class II-III
* ejection fraction \< 40 % as assessed by 2D echocardiography
* who have been optimized on Guideline Directed treatment for heart failure for at least a month prior to enrolling.
Exclusion Criteria
* Treatment with statins during the past month prior to study.
* Serum creatinine \> 3 mg/dl
* Significant liver disease: liver enzymes 2.5 folds the upper normal limit
* Malignancy
* Pregnancy or lactation
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nouran Omar
Assistant Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University Hospital Cardiology Rehab Unit
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
El Said NO, El Wakeel LM, Khorshid H, Darweesh EAG, Ahmed MA. Impact of lipophilic vs hydrophilic statins on the clinical outcome and biomarkers of remodelling in heart failure patients: A prospective comparative randomized study. Br J Clin Pharmacol. 2021 Jul;87(7):2855-2866. doi: 10.1111/bcp.14695. Epub 2021 Jan 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.